
Current Price | $17.68 | Mkt Cap | $776.0M |
---|---|---|---|
Open | $18.18 | P/E Ratio | -8.08 |
Prev. Close | $17.68 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $17.61 - $18.28 | Volume | 533,842 |
52-Wk Range | $16.55 - $50.77 | Avg. Daily Vol. | 936,903 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Current Price | $17.68 | Mkt Cap | $776.0M |
---|---|---|---|
Open | $18.18 | P/E Ratio | -8.08 |
Prev. Close | $17.68 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $17.61 - $18.28 | Volume | 533,842 |
52-Wk Range | $16.55 - $50.77 | Avg. Daily Vol. | 936,903 |
The best Bull and Bear pitches based on recency and number of recommendations.
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.
Read the most recent pitches from players about SAVA.
Recs
It has 1 drug candidate for Alzheimer's that is a long-shot for approval. Heavily-shorted stock.
Recs
The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.
Recs
They just released information of a trial they did with their treatment for Alzheimer's Disease. The results of the trial were positive, patients had an improvement in cognition and behavior. the name of the treatment/drug is Simufilam.
Find the members with the highest scoring picks in SAVA.
medeaschild (73.78) Score: +2,141.36
The Score Leader is the player with the highest score across all their picks in SAVA.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
medeaschild | 73.78 | 12/26/2018 |
![]() |
NS | $0.76 | +2,224.18% | +82.82% | +2,141.36 | 0 Comment | |
marcet | 74.31 | 3/2/2009 |
![]() |
3W | $18.82 | -6.08% | +505.40% | +511.48 | 0 Comment | |
foolrrrrrrrrrr | 26.05 | 11/13/2008 |
![]() |
1Y | $37.61 | -52.99% | +423.73% | +476.72 | 0 Comment | |
hackerbobZ | < 20 | 3/23/2009 |
![]() |
5Y | $17.65 | +0.16% | +453.59% | +453.43 | 0 Comment | |
Dennyf10 | 68.06 |
|
![]() |
1Y | $35.72 | -50.51% | +383.48% | +433.99 | 0 Comment | |
deemonfather42 | < 20 | 7/6/2009 |
![]() |
3W | $22.42 | -21.15% | +384.70% | +405.85 | 0 Comment | |
kozmo66 | < 20 | 9/22/2008 |
![]() |
3M | $38.69 | -54.31% | +255.24% | +309.55 | 0 Comment | |
MARTIJN76 | 93.77 | 10/19/2006 |
![]() |
3M | $35.60 | -50.34% | +235.83% | +286.16 | 0 Comment | |
TheDecider | 34.01 | 1/27/2011 |
![]() |
5Y | $34.90 | -49.34% | +232.22% | +281.57 | 0 Comment | |
Whereismymony | < 20 | 12/8/2006 |
![]() |
3M | $36.27 | -51.25% | +224.51% | +275.76 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.